<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369939</url>
  </required_header>
  <id_info>
    <org_study_id>HYCAN</org_study_id>
    <nct_id>NCT02369939</nct_id>
  </id_info>
  <brief_title>Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy</brief_title>
  <acronym>HYCAN</acronym>
  <official_title>Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized study to investigate the efficacy of deep regional hyperthermia in patients with
      anal carcinoma treated by standard radiochemotherapy with MMC and 5-FU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pat. with anal carcinoma and treated with standard radiochemotherapy with Mitomycin C and
      5-FU will in the experimental arm receive deep regional hyperthermia (6x).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of complete remission</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colostomy-free survival</measure>
    <time_frame>5 years after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional relapse-free survival</measure>
    <time_frame>5 years after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall relapse-free survival</measure>
    <time_frame>5 years after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>5 years after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute and late toxicity</measure>
    <time_frame>5 years after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Anal Carcinoma</condition>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33 Hyperthermia: 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Irradiation</intervention_name>
    <description>Radiotherapy 55,8 Gy - 59,4 Gy</description>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>MMC w1, w5</description>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>any brand is permitted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-FU w1, w5</description>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>any brand is permitted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermia</intervention_name>
    <description>6x deep regional hyperthermia</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Deep regional hyperthermia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven anal squamous cell carcinoma (SCC) (WHO 2004), including anal
             canal carcinoma (UICC 2002) and anal margin carcinoma (UICC 2002)

          -  All stages except T1 N0 M0 after local excision (UICC 2002)

          -  Age ≥ 18 years

          -  ECOG Status 0-1

          -  Patients that have understand protocol and signed informed consent form

          -  Sufficient bone marrow function: WBC ≥ 3,0 x 10^9/l, Platelets ≥ 100 x 10^9/l,
             Hemoglobin ≥ 10 g/dl

          -  Sufficient liver function: Bilirubin &lt; 1,5 mg/dl, SGOT, SGPT, alkaline phosphatase,
             gGT less than 3 times upper limit of normal

        Exclusion Criteria:

          -  Stage T1 N0 M0 after local excision (UICC 2002)

          -  Uncontrolled, severe cardiac dysfunction (NYHA III/IV)

          -  Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm
             disturbances requiring therapy

          -  Myocardial infarction within the past 12 months

          -  Congestive heart failure

          -  Complete bundle branch block

          -  New York Heart Association (NYHA) class III or IV heart disease

          -  Chronic inflammatory disease of the intestine

          -  Active intractable or uncontrolled infection

          -  Chronic diarrhea ( &gt; NCI CTC-Grad 1)

          -  Acute thrombosis

          -  Collagen vascular disease

          -  Cardiac pacemaker

          -  HIV-infection; Patients with hepatitis A or B virus infection, with HPV infection or
             Patients receiving immune suppressive treatment can be included

          -  Devices that preclude deep regional hyperthermia (Endoprosthesis, stent in vascular
             system, acute thrombosis)

          -  Any metal implants (with exception of non-clustered marker clips)

          -  Conditions that preclude the application of fractionated pelvic radiotherapy

          -  Conditions that preclude regular follow-up

          -  Pregnant or breast feeding women

          -  Prior pelvic radiotherapy

          -  Prior chemotherapy

          -  Drug addiction

          -  On-treatment participation on other trials

          -  Prior or concurrent malignancy or leucemia (≤ 5 years prior to enrolment in study)
             except anal cancer or non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1 if
             the patient is continuously disease-free

          -  The presence of increased radiation sensitivity, for example ataxia teleangiectatica,
             or similar

          -  Psychological, familial, sociological, or geographical condition that would preclude
             study compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Fietkau, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Universitätsklinikum Erlangen, Strahlenklinik</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rainer Fietkau, Prof. Dr.</last_name>
    <phone>++49(0)9131-85</phone>
    <phone_ext>33968</phone_ext>
    <email>st-studiensekretatiat@uk-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen, Strahlenklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Fietkau, Prof. Dr.</last_name>
      <phone>++49(0)9131-85</phone>
      <phone_ext>33968</phone_ext>
      <email>st-studiensekretariat@uk-erlangen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anal carcinoma</keyword>
  <keyword>hyperthermia</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

